FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306290820> ?p ?o ?g. }

• W4306290820 abstract "Abstract Background Small randomized clinical trials have found that patients with heart failure (HF) and atrial fibrillation (AF) randomized to an ablation strategy for AF experienced improved cardiovascular outcomes. We examined the relation in routine clinical practice. Purpose We aimed to assess if first-time pulmonary vein isolation ablation (PVI) for AF among patients with HF was associated with decrease in HF hospital admissions rates and furosemide dosage in the year after PVI compared with the year before. Methods We identified patients with HF and available left ventricular ejection fraction (LVEF) treated with a first-time PVI using the Danish Ablation Registry, and alive at 1-year follow-up. Patient comorbidities and concomitant pharmacotherapy (including furosemide dosage and HF hospital admissions) were identified utilizing Danish nationwide registries. For inclusion, patients were required to have been diagnosed with HF in an in- or outpatient setting &lt;10 years of first-time PVI or have a LVEF at the time of PVI ≤45%. Patients were grouped according to LVEF at time of PVI: ≤35%, 36–45%, and &gt;45%. For comparison of HF hospital admission and furosemide usage before and after PVI, McNemars test were used. Wilcox signed-rank test were used to test difference in furosemide dosage before and after PVI. Results We identified 668/3450 patients with HF treated with first-time PVI for AF between 2010–2017 (median age 62 years [Q1,Q3=56,69 years], 81% male, and median LVEF 45% [Q1,Q3=40,60%]). Of these, 13 patients (2%) died during one-year follow-up. Overall, 36% of patients with HF had one or more HF hospital admissions the year before PVI compared with 7% in the year after PVI (p&lt;0.0001) (Figure 1). Patients with LVEF ≤35% had the highest proportion of HF hospital admissions the year before PVI (53%) and was reduced more than 4-fold (13%) in the year after first-time PVI, with consistent findings in all LVEF groups (Figure 1). At the time of PVI, 36% of patients with HF were treated with furosemide compared with 30% in the year after PVI (p&lt;0.0001) (Figure 2). Moreover, we identified significant reductions in furosemide dose in the year after PVI compared with the year before (median dose 60 mg [Q1,Q3=30,80 mg] and 20 mg [Q1,Q3=0,60 mg], respectively, p=0.001). Here, reductions in furosemide requirements were consistent across LVEF subgroups. Conclusion Patients with HF treated with a first-time PVI strategy for AF had a 5-fold decrease in HF hospital admissions in the following year compared with the year before PVI. Among patients treated with furosemide at time of PVI, significant reductions in dose one year after PVI was identified but also significant reductions in proportion of patients requiring any furosemide at all. Funding Acknowledgement Type of funding sources: None." @default.
• W4306290820 created "2022-10-15" @default.
• W4306290820 creator A5002380962 @default.
• W4306290820 creator A5003665539 @default.
• W4306290820 creator A5007193849 @default.
• W4306290820 creator A5010249363 @default.
• W4306290820 creator A5020437293 @default.
• W4306290820 creator A5021275385 @default.
• W4306290820 creator A5024533116 @default.
• W4306290820 creator A5026197031 @default.
• W4306290820 creator A5041436196 @default.
• W4306290820 creator A5062929557 @default.
• W4306290820 creator A5068165717 @default.
• W4306290820 creator A5074029187 @default.
• W4306290820 creator A5074790747 @default.
• W4306290820 creator A5080516107 @default.
• W4306290820 creator A5081057548 @default.
• W4306290820 date "2022-10-01" @default.
• W4306290820 modified "2023-10-03" @default.
• W4306290820 title "Heart failure hospitalizations and diuretic use before and after first-time pulmonary vein isolation ablation for atrial fibrillation among patients with heart failure" @default.
• W4306290820 doi "https://doi.org/10.1093/eurheartj/ehac544.593" @default.
• W4306290820 hasPublicationYear "2022" @default.
• W4306290820 type Work @default.
• W4306290820 citedByCount "0" @default.
• W4306290820 crossrefType "journal-article" @default.
• W4306290820 hasAuthorship W4306290820A5002380962 @default.
• W4306290820 hasAuthorship W4306290820A5003665539 @default.
• W4306290820 hasAuthorship W4306290820A5007193849 @default.
• W4306290820 hasAuthorship W4306290820A5010249363 @default.
• W4306290820 hasAuthorship W4306290820A5020437293 @default.
• W4306290820 hasAuthorship W4306290820A5021275385 @default.
• W4306290820 hasAuthorship W4306290820A5024533116 @default.
• W4306290820 hasAuthorship W4306290820A5026197031 @default.
• W4306290820 hasAuthorship W4306290820A5041436196 @default.
• W4306290820 hasAuthorship W4306290820A5062929557 @default.
• W4306290820 hasAuthorship W4306290820A5068165717 @default.
• W4306290820 hasAuthorship W4306290820A5074029187 @default.
• W4306290820 hasAuthorship W4306290820A5074790747 @default.
• W4306290820 hasAuthorship W4306290820A5080516107 @default.
• W4306290820 hasAuthorship W4306290820A5081057548 @default.
• W4306290820 hasBestOaLocation W43062908201 @default.
• W4306290820 hasConcept C126322002 @default.
• W4306290820 hasConcept C164705383 @default.
• W4306290820 hasConcept C168563851 @default.
• W4306290820 hasConcept C2776131983 @default.
• W4306290820 hasConcept C2777955127 @default.
• W4306290820 hasConcept C2778198053 @default.
• W4306290820 hasConcept C2778902805 @default.
• W4306290820 hasConcept C2779161974 @default.
• W4306290820 hasConcept C2779918671 @default.
• W4306290820 hasConcept C2780689522 @default.
• W4306290820 hasConcept C3020110884 @default.
• W4306290820 hasConcept C71924100 @default.
• W4306290820 hasConcept C78085059 @default.
• W4306290820 hasConceptScore W4306290820C126322002 @default.
• W4306290820 hasConceptScore W4306290820C164705383 @default.
• W4306290820 hasConceptScore W4306290820C168563851 @default.
• W4306290820 hasConceptScore W4306290820C2776131983 @default.
• W4306290820 hasConceptScore W4306290820C2777955127 @default.
• W4306290820 hasConceptScore W4306290820C2778198053 @default.
• W4306290820 hasConceptScore W4306290820C2778902805 @default.
• W4306290820 hasConceptScore W4306290820C2779161974 @default.
• W4306290820 hasConceptScore W4306290820C2779918671 @default.
• W4306290820 hasConceptScore W4306290820C2780689522 @default.
• W4306290820 hasConceptScore W4306290820C3020110884 @default.
• W4306290820 hasConceptScore W4306290820C71924100 @default.
• W4306290820 hasConceptScore W4306290820C78085059 @default.
• W4306290820 hasIssue "Supplement_2" @default.
• W4306290820 hasLocation W43062908201 @default.
• W4306290820 hasOpenAccess W4306290820 @default.
• W4306290820 hasPrimaryLocation W43062908201 @default.
• W4306290820 hasRelatedWork W1483882493 @default.
• W4306290820 hasRelatedWork W2150788839 @default.
• W4306290820 hasRelatedWork W2348720246 @default.
• W4306290820 hasRelatedWork W2517180042 @default.
• W4306290820 hasRelatedWork W2583047656 @default.
• W4306290820 hasRelatedWork W2886924400 @default.
• W4306290820 hasRelatedWork W3029306217 @default.
• W4306290820 hasRelatedWork W3132128850 @default.
• W4306290820 hasRelatedWork W3157316619 @default.
• W4306290820 hasRelatedWork W4206242717 @default.
• W4306290820 hasVolume "43" @default.
• W4306290820 isParatext "false" @default.
• W4306290820 isRetracted "false" @default.
• W4306290820 workType "article" @default.